Objectives: Botulinum neurotoxin serotype A (BoNT/A) is a valid therapy for dystonia but repeated BoNT/A injections may induce a clinical immuno-resistance that could be overcome by using other BoNT serotypes. In vitro experiments and our preliminary investigations in vivo, indicate that botulinum neurotoxin serotype C (BoNT/C) could be an effective alternative to BoNT/A. Moreover, in cultured neurons 'in vitro' BoNT/C has been reported to be more toxic than BoNT/A.
Methods: To verify this possibility, we compare the effect of BoNT/C and BoNT/A on the motor units count in humans by using the electrophysiological motor unit number estimation (MUNE) technique ('multiple point nerve stimulation'). Preliminarily, BoNT/C and BoNT/A dosage was calibrated in a mouse hemidiaphragm neuromuscular junction preparation. Subsequently, 8 volunteers were treated with 3IU of BoNT/C in the extensor digitorum brevis muscle of one foot and 3IU of BoNT/A in the contralateral one. Other 4 subjects were similarly injected at higher doses (10IU of BoNT/C or BoNT/A) to detect a possible dose-toxic effect.
Results: In both groups, no statistically significant variations in MUNE counting or single motor unit potential size were detected after 4 months from injections, when it was evident a recovery from the BoNTs blockade.
Conclusions: We conclude that BoNT/C, similarly to BoNT/A, is safe and effective in humans and it could be proposed for a clinical use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1388-2457(02)00103-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-time PCR assays that detect genes for botulinum neurotoxin A-G subtypes.
Front Microbiol
May 2024
Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States.
The role of Real-Time PCR assays for surveillance and rapid screening for pathogens is garnering more and more attention because of its versatility and ease of adoption. The goal of this study was to design, test, and evaluate Real-Time TaqMan PCR assays for the detection of botulinum neurotoxin (/A-G) genes from currently recognized BoNT subtypes. Assays were computationally designed and then laboratory tested for sensitivity and specificity using DNA preparations containing genes from 82 target toxin subtypes, including nine bivalent toxin types; 31 strains representing other clostridial species; and an extensive panel that consisted of DNA from a diverse set of prokaryotic (bacterial) and eukaryotic (fungal, protozoan, plant, and animal) species.
View Article and Find Full Text PDFCharacterization of Serotype CD Mosaic Botulinum Neurotoxin in Comparison with Serotype C and A.
Toxins (Basel)
February 2023
Department of Food, Aroma and Cosmetic Chemistry, Faculty of Bioindustry, Tokyo University of Agriculture, Abashiri 099-2493, Hokkaido, Japan.
Botulinum neurotoxin (BoNT), produced by , cleaves proteins involved in neurotransmitter release, thereby triggering flaccid paralyses, which are responsible for botulism. BoNT is classified into seven serotypes (BoNT/A-G); BoNT/A and BoNT/B are used as medical therapeutics and anti-wrinkle reagents. In this study, we investigated the efficacy of BoNT/CD, a mosaic toxin of BoNT/C and BoNT/D, to assess its potential as a therapeutic alternative for BoNT/A.
View Article and Find Full Text PDFA Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D.
Toxins (Basel)
September 2021
Department of Anesthesia & Perioperative Care, University of California, San Francisco, Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Avenue, San Francisco, CA 94110, USA.
Article Synopsis
- Human botulism is caused by different serotypes of botulinum neurotoxin (BoNT) and this study focused on developing an antitoxin using four human monoclonal antibodies (mAbs) targeting BoNT/C, BoNT/D, and their mosaic toxins.
- The mAbs were created from human immune libraries and showed strong binding to multiple serotypes, with three undergoing evolution to enhance their affinity.
- A combination of these mAbs demonstrated effective neutralization and has potential for therapeutic and diagnostic applications, with one derivative (NTM-1634) showing safety in a Phase 1 clinical trial.
Paper-based electrochemical peptide sensor for on-site detection of botulinum neurotoxin serotype A and C.
Biosens Bioelectron
July 2021
Tor Vergata University, Department of Chemical Science and Technologies, Via Della Ricerca Scientifica, 00133, Rome, Italy; SENSE4MED, Via Renato Rascel 30, 00133, Rome, Italy. Electronic address:
Botulinum neurotoxins (BoNTs) produced by soil bacterium Clostridium botulinum are cause of botulism and listed as biohazard agents, thus rapid screening assays are needed for taking the correct countermeasures in a timely fashion. The gold standard method relies on the mouse lethality assay with a lengthy analysis time, i.e.
View Article and Find Full Text PDFOutbreak of botulism type A in dairy cows detected by MALDI-TOF mass spectrometry.
J Vet Diagn Invest
September 2020
Cornell University, College of Veterinary Medicine, Ithaca, NY (Frye, Crouch, Kelly).
Twenty-eight lactating dairy cattle in New York State were exposed to botulism toxin; 12 died and 16 recovered but never returned to full productivity. Pieces of a raccoon carcass were found in the total mixed ration on the first day of the outbreak. Clinical signs included anorexia, decreased milk production, decreased tongue tone, profound weakness, and recumbency.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!